Scholar Rock (NASDAQ:SRRK) Earns “Buy” Rating from HC Wainwright

Scholar Rock (NASDAQ:SRRK)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $58.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 22.29% from the stock’s previous close.

SRRK has been the subject of several other research reports. Citigroup initiated coverage on Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 price objective for the company. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Friday, November 14th. Wolfe Research initiated coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective for the company. JPMorgan Chase & Co. upped their target price on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Finally, UBS Group began coverage on shares of Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price for the company. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $54.14.

Scholar Rock Trading Up 7.0%

Scholar Rock stock opened at $47.43 on Tuesday. The company has a market cap of $4.84 billion, a price-to-earnings ratio of -13.83 and a beta of 0.70. The firm has a 50-day moving average of $45.32 and a 200-day moving average of $39.14. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. Scholar Rock has a one year low of $22.71 and a one year high of $49.82.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period in the prior year, the business posted ($0.64) EPS. On average, equities analysts expect that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In other Scholar Rock news, insider Caryn Parlavecchio sold 9,035 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $420,398.55. Following the completion of the sale, the insider directly owned 169,087 shares in the company, valued at $7,867,618.11. This trade represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jing L. Marantz sold 4,157 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $193,425.21. Following the completion of the transaction, the insider directly owned 126,012 shares in the company, valued at $5,863,338.36. The trade was a 3.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 208,470 shares of company stock worth $9,201,778. 13.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Scholar Rock

Several institutional investors have recently added to or reduced their stakes in SRRK. AQR Capital Management LLC increased its position in Scholar Rock by 609.3% during the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after buying an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after acquiring an additional 5,831 shares in the last quarter. Millennium Management LLC increased its position in Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after acquiring an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after acquiring an additional 34,594 shares during the period. Finally, Strs Ohio acquired a new stake in Scholar Rock in the 1st quarter worth about $77,000. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock News Summary

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: BMO Capital Markets raised its price target from $50 to $70 and kept an “outperform” rating (~47.6% upside vs. the current price). BMO Raises PT to $70
• Positive Sentiment: Citigroup raised its target to $58 and maintained a “buy” rating (~22% upside). Citigroup Raises PT to $58
• Positive Sentiment: Piper Sandler raised its target to $58 and kept an “overweight” rating (similar ~22% upside). Piper Sandler PT Raise Street Insider
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and a $58 target. HC Wainwright Reaffirmation TickerReport
• Positive Sentiment: Q4 results narrowly beat expectations — reported EPS (net loss) was ($0.76) vs. consensus (~$0.86), which analysts viewed positively relative to estimates. Earnings Release / Summary
• Neutral Sentiment: Full earnings and Q&A transcripts are now available (multiple outlets posted call transcripts), useful for digging into pipeline updates and management tone. Seeking Alpha Transcript InsiderMonkey Transcript
• Negative Sentiment: Despite the beat, the corrected press release clarifies net loss per share was $0.76 for Q4 vs. $0.61 a year earlier — an increase in the loss year‑over‑year, underscoring ongoing unprofitability. BusinessWire Correction

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).